



# INVITATION

**Thursday 4<sup>th</sup> March 2021**

***Heart Failure – what a General Practitioner needs to know and can do in 2021***

***Speaker: Dr Mark Davis, Cardiologist***

You are invited to attend a Novartis-Sponsored Educational Meeting **Thursday 4<sup>th</sup> March 2021**  
The meeting will be held at **Novotel Tainui Hamilton, 7 Alma Street, Hamilton** from 5.45pm.



## **Agenda**

<b>Time</b>	<b>Session</b>	<b>Speaker</b>
5.45pm	Registration and beverage service	
6.15pm	Dinner served	
6.45-7.45pm	Presentation	Dr Mark Davis
7.45pm	Q&A, dessert served	
8.15pm	Meeting Close	

Dinner and beverage service will be provided.

I hope you are able to attend this interesting, interactive and thought-provoking event.

Yours sincerely,

Anita Timms  
Key Account Manager 021 639 955

***We apologise we are unable to reimburse parking fees.***

If you would like to attend this meeting, please return the following form to  
**Anita.timms@novartis.com** or fax 64 9 361 8181 before **25<sup>th</sup> February 2021**.



# RSVP

## Please return to

**anita.timms@novartis.com**  
**or fax 64 9 361 8181**  
**before 25<sup>th</sup> February 2021**

Event 5 March 2021 Hamilton

Doctors name/s	
Surgery name	
Email address	<b>If circumstances change and we need to change this meeting into a virtual online meeting at short notice, it is important that we have your email address.</b>
Phone number	
Dietary requirements	
Signature	

**I have read and understood the privacy notice and hereby consent to it - please tick.**



By providing your personal information to Novartis New Zealand Limited or its related bodies corporate (Novartis), you consent to Novartis collecting, storing and using your personal information in accordance with the Novartis Privacy Policy. In particular, you consent to Novartis using your personal information to communicate with you about Novartis products and/or to support your use of those products, and you consent to Novartis using your personal information for audit or inspection purposes. Novartis reserves the right to use aggregated and de-identified data collected through this activity. You also consent to Novartis using your personal information to (where applicable) invite you to, or arrange your participation in, activities managed by (or on behalf of) Novartis. Novartis is committed to patient safety. In accordance with regulatory obligations Novartis processes reports of adverse events experienced by patients taking a Novartis product, when identified by a Novartis representative (or by a third party acting on behalf of Novartis). Novartis Patient Safety may contact you or your healthcare professional in order to collect further information on the adverse event. This information may be shared with health authorities or other Pharmaceutical companies with whom Novartis has a license agreement and third parties we work with for the purpose of safety reporting. Your information may be stored on servers located in jurisdictions outside of New Zealand, such as Switzerland, United Kingdom, United States of America and others. Some of those countries may not offer the same level of privacy protection as in New Zealand. However, Novartis will enter into agreements with its third-party service providers to keep your information secure and provide adequate protection for your data. You are not obliged to provide personal information. However, if you do not provide information you may not, for example, be able to participate fully in activities managed by us. You have the right to access, update or correct your personal information and/or decline to receive communications from Novartis. To find out how, please refer to our Privacy Policy or contact our Privacy Officer at Novartis New Zealand Ltd, Mairangi Bay, Private Bag 65904 Auckland 0754, New Zealand. Phone: +64 9 361 8100 Email: [privacy.au@novartis.com](mailto:privacy.au@novartis.com).

PRESCRIPTION MEDICINE. Entresto® 24mg/26mg, 49mg/51mg, 97mg/103mg (sacubitril/valsartan) film coated tablets. Consult full Data Sheet before prescribing, for information on dosage, contraindications, precautions, interactions and adverse effects. The data sheet is available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). Entresto is a fully funded medicine under special authority – please consult [www.pharmac.govt.nz](http://www.pharmac.govt.nz). Entresto is a registered trademark of Novartis AG, Switzerland. Novartis New Zealand Limited, Auckland. Ph 0800 652 422

NZ-00760 June 2020, TAPs NA12071 BGA200610

